Charged Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative Pathogens

ACS Medicinal Chemistry Letters

Volumn 7, Issue 7, 2016, Pages 692-696

  Scocchera, Eric ^a   Reeve, Stephanie M ^a   Keshipeddy, Santosh ^a   Lombardo, Michael N ^a   Hajian, Behnoush ^a   Sochia, Adrienne E ^b   Alverson, Jeremy B ^b   Priestley, Nigel D ^b   Anderson, Amy C ^a   Wright, Dennis L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

antifolate; Dihydrofolate reductase; Escherichia coli; methotrexate; MRSA; Staphylococcus aureus; trimethoprim

Indexed keywords

ANTIBIOTIC AGENT; CARBOXYLIC ACID; CIPROFLOXACIN; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FOLIC ACID ANTAGONIST; METHYL GROUP; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INHIBITORY CONCENTRATION; MAMMAL CELL; METABOLIC STABILITY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON TRANSPORT; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; THERAPEUTIC INDEX; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; X RAY CRYSTALLOGRAPHY;

EID: 84978653695     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00120     Document Type: Article

References (24)

1. Hagner, N.; Joerger, M. Cancer chemotherapy: targeting folic acid synthesis Cancer Manage. Res. 2010, 2, 293-301 10.2147/CMAR.S10043
2. Zhou, W.; Scocchera, E.; Wright, D.; Anderson, A. Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs MedChemComm 2013, 4, 908-915 10.1039/c3md00104k
3. Bennett, B.; Wan, Q.; Ahmad, M.; Langan, P.; Dealwis, C. X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design J. Struct. Biol. 2009, 166, 162-171 10.1016/j.jsb.2009.01.001
4. Sawaya, M.; Kraut, J. Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence Biochemistry 1997, 36, 586-603 10.1021/bi962337c
5. Li, R.; Sirawaraporn, R.; Chitnumsub, P.; Sirawaraporn, W.; Wooden, J.; Athappilly, F.; Turley, S.; Hol, W. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs J. Mol. Biol. 2000, 295, 307-323 10.1006/jmbi.1999.3328
6. Burchall, J.; Hitchings, G. Inhibitor Binding Analysis of Dihydrofolate Reductases from Various Species Mol. Pharmacol. 1965, 1, 126-136
7. Kopytek, S.; Dyer, J.; Knapp, G.; Hu, J. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli Antimicrob. Agents Chemother. 2000, 44, 3210-3212 10.1128/AAC.44.11.3210-3212.2000
8. Viswanathan, K.; Frey, K.; Scocchera, E.; Martin, B.; Swain, P.; Alverson, J.; Priestley, N.; Anderson, A.; Wright, D. Toward new Therapeutics for Skin and Soft Tissue Infections: Propargyl-linked Antifolates Are Potent Inhibitors of MRSA and Streptococcus pyogenes PLoS One 2012, 7 (2) e29434 10.1371/journal.pone.0029434
9. Kruszewska, H.; Zareba, T.; Tyski, S. Antimicrobial activity of selected non-antibiotics-activity of methotrexate against Staphylococcus aureus strains Acta Polym. Pharm. 2000, 57S, 117-119
10. Frei, C.; Miller, M.; Lewis, J.; Lawson, K.; Hunter, J.; Oramasionwu, C.; Talbert, R. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections J. Am. Board Fam. Med. 2010, 23, 714-719 10.3122/jabfm.2010.06.090270
11. Khawcharoenporn, T.; Tice, A. Empiric outpatient therapy with trimethoprim-sulfamethoxazole, cephalexin, or clindamycin for cellulitis Am. J. Med. 2010, 123, 942-950 10.1016/j.amjmed.2010.05.020
12. Le, J.; Lieberman, J. Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children Pharmacotherapy 2006, 26, 1758-1770 10.1592/phco.26.12.1758
13. Wood, J.; Smith, D.; Baker, E.; Brecher, S.; Gupta, K. Has the emergence of community-associated methicillin-resistant Staphylococcus aureus increased trimethoprim-sulfamethoxazole use and resistance?: a 10-year time series analysis Antimicrob. Agents Chemother. 2012, 56, 5655-5660 10.1128/AAC.01011-12
14. O'Shea, R.; Moser, H. Physicochemical properties of antibacterial compounds: implications for drug discovery J. Med. Chem. 2008, 51, 2871-2878 10.1021/jm700967e
15. Keshipeddy, S.; Reeve, S.; Anderson, A.; Wright, D. Nonracemic antifolates stereoselectively recruit alternate cofactors and overcome resistance in S. aureus J. Am. Chem. Soc. 2015, 137, 8983-8990 10.1021/jacs.5b01442
16. Lamb, K.; Lombardo, M.; Alverson, J.; Priestley, N.; Wright, D.; Anderson, A. Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity Antimicrob. Agents Chemother. 2014, 58, 7484-7491 10.1128/AAC.03555-14
17. Frey, K.; Viswanathan, K.; Wright, D.; Anderson, A. Prospectively screening novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance Antimicrob. Agents Chemother. 2012, 56, 3556-3562 10.1128/AAC.06263-11
18. Zhou, W.; Viswanathan, K.; Hill, D.; Anderson, A.; Wright, D. Acetylenic linkers in lead compounds: A study of the stability of the propargyl-linked antifolates Drug Metab. Dispos. 2012, 40, 2002-2008 10.1124/dmd.112.046870
19. Frey, K.; Lombardo, M.; Wright, D.; Anderson, A. Towards the Understanding of Resistance Mechanisms in Clinically Isolated Trimethoprim-resistant, Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase J. Struct. Biol. 2010, 170, 93-97 10.1016/j.jsb.2009.12.011
20. Fox, K.; Karplus, A. Old yellow enzyme at 2A resolution: overall structure, ligand binding and comparison with related flavoproteins Structure 1994, 2, 1089-1105 10.1016/S0969-2126(94)00111-1
21. Oppenheimer, N. The primary acid product of DPNH Biochem. Biophys. Res. Commun. 1973, 50, 683-690 10.1016/0006-291X(73)91298-9
22. Pankey, G.; Sabath, L. Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action its the Treatment of Gram-Positive Bacterial Infections Clin. Infect. Dis. 2004, 38, 864-870 10.1086/381972
23. Jakeman, D.; Sadeghi-Khomami, A. A b-(1,2)-glycosynthase and an attempted selection method for the directed evolution of glycosynthases Biochemistry 2011, 50, 10359-10366 10.1021/bi201438q
24. Ruiz, N.; Falcone, B.; Kahne, D.; Silhavy, T. Chemical conditionality: a genetic strategy to probe organelle assembly Cell 2005, 121, 307-317 10.1016/j.cell.2005.02.014